Abstract
The tyrosine kinase inhibitor sorafenib is the first-line treatment for patients with hepatocellular carcinoma (HCC), in which hyperlipidemia and type......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
